医学
阿维巴坦
广谱
抗菌剂
重症监护医学
β-内酰胺酶抑制剂
头孢他啶/阿维巴坦
抗生素
微生物学
铜绿假单胞菌
生物
细菌
组合化学
遗传学
化学
头孢他啶
作者
Maroun Bou Zerdan,Sally Al Hassan,Waleed Shaker,Rayan El Hajjar,Sabine Allam,Morgan Bou Zerdan,Amal Naji,Nabil Zeineddine
出处
期刊:Journal of Clinical Medicine Research
[Elmer Press, Inc.]
日期:2022-07-01
卷期号:14 (7): 251-259
被引量:1
摘要
Carbapenem resistance, an emerging global health problem, compromises the treatment of infections caused by nosocomial pathogens. Preclinical and clinical trials demonstrate that a new generation of carbapenemases inhibitors, together with the recently approved avibactam, relebactam and vaborbactam, would address this resistance. Our review summarizes the latest developments related to carbapenemase inhibitors synthesized to date, as well as their spectrum of activity and their current stage of development. A particular focus will be on β-lactam/β-lactamase inhibitor combinations that could potentially be used to treat infections caused by carbapenemase-producer pathogens. These new combinations mark a critical step forward the fight against antimicrobial resistance.
科研通智能强力驱动
Strongly Powered by AbleSci AI